Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
1998-12-31
pubmed:abstractText
Abnormalities in mucin-type glycoprotein expression have been documented in a variety of cancers, identifying these molecules as targets for immunologically based therapies and prognostic/diagnostic assays. We examined the expression of the membrane-bound MUC1 mucin in normal, histologically atypical, and neoplastic lung to determine its potential contribution to lung carcinogenesis. In vivo, intense MUC1 immunoreactivity was present in normal type II pneumocytes as well as in a range of atypical lesions derived from type II cells and >60% of primary and metastatic non-small cell lung cancers. Expression was not associated with altered survival, although it was highly correlated with the adenocarcinoma histology. A carcinogenesis model using 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone-exposed hamsters revealed that MUC1 mRNA increased prior to the histological appearance of tumors. In vitro studies using MUC1 expressing non-small cell lung cancer cell lines revealed that differentiation away from a type II cell lineage was associated with dramatic down-regulation of MUC1. We propose that MUC1 is a powerful new marker for the type II pneumocyte cell lineage that allows us to follow the type II pneumocyte lineage during the process of lung carcinogenesis.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5582-9
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:9850098-Animals, pubmed-meshheading:9850098-Carcinogens, pubmed-meshheading:9850098-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:9850098-Cell Differentiation, pubmed-meshheading:9850098-Cell Lineage, pubmed-meshheading:9850098-Cricetinae, pubmed-meshheading:9850098-Down-Regulation, pubmed-meshheading:9850098-Female, pubmed-meshheading:9850098-Histone Deacetylase Inhibitors, pubmed-meshheading:9850098-Humans, pubmed-meshheading:9850098-Immunohistochemistry, pubmed-meshheading:9850098-Lung, pubmed-meshheading:9850098-Lung Neoplasms, pubmed-meshheading:9850098-Male, pubmed-meshheading:9850098-Mesocricetus, pubmed-meshheading:9850098-Middle Aged, pubmed-meshheading:9850098-Mucin-1, pubmed-meshheading:9850098-Nitrosamines, pubmed-meshheading:9850098-Oligopeptides, pubmed-meshheading:9850098-Peptide Fragments, pubmed-meshheading:9850098-Pulmonary Alveoli, pubmed-meshheading:9850098-RNA, Messenger, pubmed-meshheading:9850098-Tumor Markers, Biological
pubmed:year
1998
pubmed:articleTitle
MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis.
pubmed:affiliation
Cell and Cancer Biology Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Rockville, Maryland 20850, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't